Yıl: 2021 Cilt: 36 Sayı: 3 Sayfa Aralığı: 409 - 413 Metin Dili: İngilizce DOI: 10.5505/tjo.2020.2615 İndeks Tarihi: 17-05-2022

Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case

Öz:
Dear Editor, Testicular cancer (TC) is very rare in clinical practice. It represents only 1-2% of all cancers.[1] However, TC is the most common malignancy in men between 15 and 40 years old.[2] Race, cryptorchidism, genetics, maternal estrogen exposure, and previous TC are main known risk factors.[3,4] Western and Northern Europe populations have significantly high incidence for TC.[5] Pathological classification of TCs consists of germ cell tumors (GCT), stromal tumors, ITGCN, and others. More than 90% of TC has GCT histology.[6] GCT is divided into 2 main subgroups such as seminomas and non-seminomatous tumors. Non-seminomatous GCT has 5 subtypes such as embryonal carcinoma, yolk sac tumors, choriocarcinoma, teratoma, and mixed tumors. Our patient has mixed GCT histology. Average age of presentation of mixed GCT is 30 years old.[7] Any combination of histological subtypes is formally possible, although admixture of embryonal carcinoma and teratoma is more frequent.[8]
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
  • 1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337(4):242.
  • 2. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA, et al. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010;19(5):1151–9.
  • 3. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: An overview. Int J Cancer 2005;116(3):331–9.
  • 4. Shankar S, Davies S, Giller R, Krailo M, Davis M, Gardner K, et al. In utero exposure to female hormones and germ cell tumors in children. Cancer 2006;106(5):1169–77.
  • 5. Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 2018;97(37):e12390.
  • 6. Bahrami A, Ro JY, Ayala AG. An overview of testicular germ cell tumors. Arch Pathol Lab Med 2007;131(8):1267–80.
  • 7. Konstantinos S, Panagiotis P, Georgios P, Galariotis N, Olympitis M, Moschouris H, et al. Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: A case report. Cases J 2009;2:9299.
  • 8. Mostofi FK, Sesterhenn IA. Pathology of germ cell tumors of testes. Prog Clin Biol Res 1985;203:1–34.
  • 9. Keske M, Canda AE, Yalcin S, Kilicarslan A, Kibar Y, Tuygun C, et al. Is testis-sparing surgery safe in small testicular masses? Results of a multicentre study. Can Urol Assoc J 2017;11(3–4):E100–4.
  • 10. Khan MJ, Bedi N, Rahimi MN, Kalsi J. Testis sparing surgery for small testicular masses and frozen section assessment. Cent European J Urol 2018;71(3):304–9.
  • 11. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn- Cedermark G, Fizazi K, et al. Guidelines on testicular cancer: 2015 update. Eur Urol 2015;68(6):1054–68.
  • 12. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: A clinical review. Ann Oncol 2005;16(6):863–8.
  • 13. Heidenreich A, Weissbach L, Holtl W, Albers P, Kliesch S, Köhrmann KU, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166(6):2161–5.
  • 14. Sivakumar R, Sivaraman PB, Mohan-Babu N, Jainul- Abideen MI, Kalliyappan P, Balasubramanian K. Radiation exposure impairs luteinizing hormone signal transduction and steroidogenesis in cultured human leydig cells. Toxicol Sci 2006;91(2):550–6.
  • 15. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European germ cell cancer consensus group (EGCCCG): Part I. Eur Urol 2008;53(3):478–96.
  • 16. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, et al. Effect of graded testicular dose of radiotherapy in patients treated for carcinoma-in situ in the testis. J Clin Oncol 2002;20(6):1537–43.
  • 17. Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G, Jørgensen N. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 2009;75(3):672–6.
  • 18. Giwercman A, von der Maase H, Berthelsen JG, Rørth M, Bertelsen A, Skakkebaek NE. Localized irradiation of testes with carcinoma in situ: Effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73(3):596–603.
  • 19. Dieckmann KP, Wilken S, Loy V, Matthies C, Kleinschmidt K, Bedke J, et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German testicular cancer study group. Ann Oncol 2013;24(5):1332–7.
  • 20. Hansen SW, Berthelsen JG, von der Maase H. Longterm fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990;8(10):1695–8.
  • 21. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jäger N, Klingmüller D.. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 1997;158(3):844–50.
  • 22. Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol 2014;32(6):571–8.
  • 23. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: A population-based study of 29, 515 U.S. men. J Natl Cancer Inst 2005;97(14):1056–66.
  • 24. Klatte T, de Martino M, Arensmeier K, Reiher F, Allhoff EP, Klatte D. Management and outcome of bilateral testicular germ cell tumors: A 25-year single center experience. Int J Urol 2008;15(9):821–6.
  • 25. Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol 2005;44(6):529–36.
  • 26. Che M, Tamboli P, Ro JY, Park DS, Ro JS, Amato RJ, et al. Bilateral testicular germ cell tumors: Twenty-year experience at M. D. Anderson cancer center. Cancer 2002;95(6):1228–33.
  • 27. Lv ZJ, Wu S, Dong P, Yao K, He YY, Gui YT, et al. Clinical outcomes in patients with stage I non-seminomatous germ cell cancer. Asian J Androl 2013;15(4):558–63.
  • 28. Mezvrishvili Z, Managadze L. Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer. Int Urol Nephrol 2006;38(3–4):621–4.
  • 29. Rabbani F, Sheinfeld J, Farivar-Mohseni H, Leon A, Rentzepis MJ, Reuter VE, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse. J Clin Oncol 2001;19(7):2020–5.
  • 30. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18(12):2413–8.
  • 31. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994;44(4):548–52.
  • 32. McLeod DG, Weiss RB, Stablein DM, Muggia FM, Paulson DF, Ellis JH, et al. Staging relationships and outcome in early stage testicular cancer: A report from the Testicular cancer ıntergroup study. J Urol 1991;145(6):1178–83.
  • 33. Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Günther RW, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?-results of a study in 50 patients. Urology 1999;54(5):900–4.
  • 34. de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: Results of the German multicentre trial. Ann Oncol 2008;19(9):1619–23.
  • 35. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F] Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: The German multicenter positron emission tomography study group. J Clin Oncol 2008;26(36):5930–5.
APA Demircan N, Akmansu M, Çetin S, Sozen T (2021). Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. , 409 - 413. 10.5505/tjo.2020.2615
Chicago Demircan Niyazi Volkan,Akmansu Muge,Çetin Serhat,Sozen Tevfik Sinan Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. (2021): 409 - 413. 10.5505/tjo.2020.2615
MLA Demircan Niyazi Volkan,Akmansu Muge,Çetin Serhat,Sozen Tevfik Sinan Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. , 2021, ss.409 - 413. 10.5505/tjo.2020.2615
AMA Demircan N,Akmansu M,Çetin S,Sozen T Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. . 2021; 409 - 413. 10.5505/tjo.2020.2615
Vancouver Demircan N,Akmansu M,Çetin S,Sozen T Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. . 2021; 409 - 413. 10.5505/tjo.2020.2615
IEEE Demircan N,Akmansu M,Çetin S,Sozen T "Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case." , ss.409 - 413, 2021. 10.5505/tjo.2020.2615
ISNAD Demircan, Niyazi Volkan vd. "Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case". (2021), 409-413. https://doi.org/10.5505/tjo.2020.2615
APA Demircan N, Akmansu M, Çetin S, Sozen T (2021). Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. Türk Onkoloji Dergisi, 36(3), 409 - 413. 10.5505/tjo.2020.2615
Chicago Demircan Niyazi Volkan,Akmansu Muge,Çetin Serhat,Sozen Tevfik Sinan Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. Türk Onkoloji Dergisi 36, no.3 (2021): 409 - 413. 10.5505/tjo.2020.2615
MLA Demircan Niyazi Volkan,Akmansu Muge,Çetin Serhat,Sozen Tevfik Sinan Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. Türk Onkoloji Dergisi, vol.36, no.3, 2021, ss.409 - 413. 10.5505/tjo.2020.2615
AMA Demircan N,Akmansu M,Çetin S,Sozen T Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. Türk Onkoloji Dergisi. 2021; 36(3): 409 - 413. 10.5505/tjo.2020.2615
Vancouver Demircan N,Akmansu M,Çetin S,Sozen T Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case. Türk Onkoloji Dergisi. 2021; 36(3): 409 - 413. 10.5505/tjo.2020.2615
IEEE Demircan N,Akmansu M,Çetin S,Sozen T "Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case." Türk Onkoloji Dergisi, 36, ss.409 - 413, 2021. 10.5505/tjo.2020.2615
ISNAD Demircan, Niyazi Volkan vd. "Organ Sparing Approach in Bilateral Testis Tumors: A Short Review of the Literature with a Featuring Case". Türk Onkoloji Dergisi 36/3 (2021), 409-413. https://doi.org/10.5505/tjo.2020.2615